The Chinese team focused on cross-species genetic engineering drug research and development completed tens of millions of yuan angel round financing

Recently, Galileo Capital announced the completion of the angel round investment in Micro Evolution (Beijing) Medical Technology Co., Ltd. (referred to as Micro Evolution Medical).

Micro-evolutionary medicine, a cross-species tumor gene therapy service provider established on November 20, 2023, takes miRNA repair therapy mediated by plant RDR1 protein as the core technology, and provides a new solution for the clinical needs of refractory recurrence and incurable drugs. This therapy has high market potential and value, and is expected to become the first brand-new broad-spectrum anti-tumor platform suitable for multiple cancer indications.

The first technology of micro-evolutionary medicine, miRNA repair therapy mediated by plant RDR1 protein, mediates miRNA repair in human tumor cells through the expression system of plant genes, thus achieving the purpose of inhibiting tumor growth. This technology not only provides a new solution for clinical needs, but also has wide applicability and broad market prospects.

As an angel wheel investor in micro-evolution medical care, Galileo Capital spoke highly of the innovative technology and market potential of micro-evolution medical care. Galileo Capital said that the technological innovation and business model of micro-evolutionary medical care are in line with its investment philosophy, and it is believed that micro-evolutionary medical care will have a better development in the future.

Team Background

Evolutionary Medicine is led by Professor Du Peng, a national professor in Peking University. The founding members of the team are from Tsinghua, Peking University, Chinese Academy of Sciences, etc., and have absorbed industry veterans. The previous research results of the project were published in top academic journals such as Cell, Nature, Trends in cell biology, etc., which aroused high praise from international peers and was recommended by highlights such as Nature series. In addition, the project was funded by the subversive technological innovation project of the Ministry of Science and Technology in the early stage. The project will develop the first completely autonomous and controllable First in class anti-cancer platform, build barriers and guarantees for cancer treatment in China, and strive to become a global leader in CGT treatment.

Technical Innovation

Evolutionary Medicine focuses on the research and development of cross-species genetic engineering drugs. The project originated from the first source innovation discovery led by Peking University's team in the world-repairing abnormal miRNA specific in tumor cells through plant protein to fight cancer in a broad spectrum. Through big data mining, the project reported the structural defects of miRNA in almost all tumors for the first time in the world, and then learned from the idea of cross-species and evolution to find plant immune proteins for repairing defects. The project is the first cross-species tumor gene therapy platform based on miRNA repair, which overcomes the problems of high toxicity, drug resistance and low response of traditional therapies, provides a new scheme for the clinical needs of refractory recurrence and no cure, and forms a substitute for existing therapies, with high market value.